Company news

Royalty Pharma plc news in 2026

Royalty Pharma plc's news releases, calls and decks from 2026, newest first.

View company

Royalty Pharma reports third quarter 2026 results

November 4, 2026

Royalty Pharma declares fourth quarter 2026 dividend

October 16, 2026

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

October 9, 2026

Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program

September 15, 2026

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

September 4, 2026

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

August 12, 2026

Royalty Pharma reports second quarter 2026 results

August 5, 2026

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

August 3, 2026

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

July 23, 2026

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

July 22, 2026

Royalty Pharma declares third quarter 2026 dividend

July 17, 2026

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

July 15, 2026

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Q1 2026 Financial Results Call Transcript

May 13, 2026

Royalty Pharma to present at upcoming investor conferences

May 7, 2026

Royalty Pharma reports first quarter 2026 results

May 6, 2026

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

April 21, 2026

Royalty Pharma Declares Second Quarter 2026 Dividend

April 17, 2026

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

April 14, 2026

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

March 29, 2026

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

March 27, 2026

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

March 22, 2026

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

March 2, 2026

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

March 1, 2026

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

March 1, 2026

Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

February 26, 2026

Royalty Pharma Reports Q4 and Full Year 2025 Results

February 11, 2026

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

January 20, 2026

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 10, 2026

Royalty Pharma Announces Dividend Increase

January 9, 2026

Calls in 2026

Decks in 2026